Tech Company Inital Public Offerings
Graphite Bio IPO
Graphite Bio, operating out of San Francisco, had an IPO event on 6/25/2021.
Transaction Overview
Company Name
Announced On
6/25/2021
Transaction Type
IPO
Amount
$212,500,000
Proceeds Purpose
Use of proceeds for the Graphite Bio IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
279 E. Grand Ave. 430
San Francisco, CA 94025
USA
San Francisco, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a broad range of severe diseases. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Josh Lehrer
Chief Operating Officer
Katherine Stultz
VP - Bus. Development
Philip Gutry
Browse more venture capital transactions:
Prev: 6/25/2021: Syndio venture capital transaction
Next: 6/25/2021: Deserve venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs